FDA clears implantable nerve stimulation system

The FDA has granted clearance to Neuspera Medical for its novel implantable system to treat chronic peripheral nerve pain.

According to a press release from Neuspera, the system comprises a micro-implant that delivers wireless neurostimulation therapy through a wearable transmitter and iPad-based clinician programmer. The ultra-miniaturized system is 75 times smaller than the smallest implantable pulse generators available and provides deeper anatomical targets compared with current technologies.

“The Neuspera ultra-miniaturized system has the potential to revolutionize the way physicians treat patients battling chronic pain while restoring patients’ health and quality of life,” Steffen Hovard, CEO of Neuspera Medical, stated in the release. “We look forward to bringing this innovative technology to physicians and patients in the U.S.”